title: A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
abstract: Prior studies of patients with dementia have found similar qualitative patterns of cerebral glucose utilization with [18F]2-fluoro-2-deoxyglucose (FDG) PET and of putative muscarinic receptor activity with [123I]3-quinuclidinyl-4-iodobenzilate (IQNB). This raised doubts about whether receptor binding determines IQNB distribution and whether clinical information in IQNB scans is unique. To compare the methods directly, 4 normal volunteers and 7 patients with dementia underwent FDG PET and high-resolution IQNB SPECT scans. In normal subjects, relative regional activity from the paired scans was only weakly correlated (r = 0.29). Some regions (e.g., thalamus, frontal cortex) showed a clear disassociation of activity. In demented patients, IQNB scans tended to show larger defects than FDG scans, although one focal defect appeared only with PET. Results suggest that IQNB SPECT data are not primarily related to general physiological activity or regional cerebral blood flow and are not explained by attenuation or volume-averaging artifacts. Further studies should investigate whether IQNB scanning is a more sensitive in vivo measure of the extent of Alzheimer's disease than is FDG PET.
authors.affiliation: Clinical Brain Disorders Branch, National Institute of Mental Health, St. Elizabeths, Washington, DC 20032.
authors.forename: D R
authors.initials: DR
authors.lastname: Weinberger
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.forename: R C
authors.initials: RC
authors.lastname: Reba
authors.forename: U
authors.initials: U
authors.lastname: Mann
authors.forename: R
authors.initials: R
authors.lastname: Coppola
authors.forename: R
authors.initials: R
authors.lastname: Gibson
authors.forename: J
authors.initials: J
authors.lastname: Gorey
authors.forename: A
authors.initials: A
authors.lastname: Braun
authors.forename: T N
authors.initials: TN
authors.lastname: Chase
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000503:physiopathology; D001786:Blood Glucose / Q000378:metabolism*; D001921:Brain / Q000098:blood supply* / Q000000981:diagnostic imaging; D002540:Cerebral Cortex / Q000098:blood supply / Q000000981:diagnostic imaging; D003704:Dementia / Q000000981:diagnostic imaging* / Q000503:physiopathology; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007457:Iodine Radioisotopes; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008953:Models, Anatomic; D009483:Neuropsychological Tests; D011813:Quinuclidinyl Benzilate / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011950:Receptors, Cholinergic / Q000502:physiology*; D012016:Reference Values; D012039:Regional Blood Flow / Q000502:physiology; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D001786:Blood Glucose; D007457:Iodine Radioisotopes; D011950:Receptors, Cholinergic; D019788:Fluorodeoxyglucose F18; D011813:Quinuclidinyl Benzilate; C040062:3-quinuclidinyl-4-iodobenzilate; D003847:Deoxyglucose